Biohaven (BHVN) Completes Enrollment in Phase 2 Obesity Study of Taldefgrobep Alfa.
Share this article
Corporate
Score 75
Bullish
Biohaven (BHVN) Completes Enrollment in Phase 2 Obesity Study of Taldefgrobep Alfa
Mar 27, 2026 07:29 UTC
BHVN, XLV, IHE
Short term
Related Articles
Score 25
Paramount, Warner Bros. Lag Behind Disney, Universal in Animated Film Releases
Mar 28, 11:00
Score 65
Bullish
New $1 Billion Airport Near Delhi to Test India’s Buildout Boom
Mar 28, 00:00
Score 75
Bearish
Fund With Anthropic Stake Slides in Post-Listing Reversal
Mar 27, 22:43
Score 55
Bullish
Kailera Therapeutics Files for US IPO to Fund Obesity Drugs
Mar 27, 21:43
Stay Ahead of the Markets
Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.